View profile

FarmaKology Newsletter - Issue #26

Revue
 
Would you like to submit an article, some interesting news, or get your startup featured? Send whatev
 

FarmaKology

December 10 · Issue #26 · View online
FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "abdul@farmakology.com".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to “abdul@farmakology.com”, and happy to have you featured on our newsletter (+1950 Subscribers ) !

Today's Startup
twoXAR 
twoXAR is a pharmaceutical company that has built a development portfolio targeting more than 18 different diseases. twoXAR’s unique approach to drug discovery combines steps from the traditional multi-step approach to R&D that severely limits the pace of drug discovery. This novel method – coupled with the company’s proprietary AI-driven platform – enables twoXAR to select a disease and initiate in vivo testing in months, instead of years.
News
Sanofi and Synthorx, Inc., a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Synthorx for $68 per share in cash, which represents an aggregate equity value of approximately $2.5 billion (on a fully diluted basis).
Omnicell, Inc., a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, has entered into an agreement with Kit Check™ to offer Bluesight™ for Controlled Substances diversion prevention software, helping customers to gain better visibility of controlled substances across the pharmacy supply chain.
Healx Ltd., the AI-powered biotechnology company focused on developing breakthrough treatments for rare diseases, today announces it has entered into an agreement with Boehringer Ingelheim to identify indications related to rare neurological diseases.
The world’s first male birth control injection is soon going to be launched by India. It is a long-lasting, non – hormonal contraceptive measure for men which will remain effective for 13 years. It will serve as an alternative to surgical vasectomy.
Research & Study
Podcast
pharmaphorum Podcast - Life sciences leadership: the pharmaphorum podcast | Listen via Stitcher for Podcasts
Job Opportunities
Upcoming Events
Video
How does chemotherapy work? - Hyunsoo Joshua No
Did you enjoy this issue?
If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue